We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Organogenesis (ORGO) to Post Q3 Earnings: What's in Store?
Read MoreHide Full Article
We expect investors to focus on the sales performance of Organogenesis Holdings’ (ORGO - Free Report) two segments — Advanced Wound Care, and Surgical & Sports Medicine — when it reports third-quarter 2021 results on Nov 9, after market close.
The company’s earnings surprise history is pretty impressive. It surpassed expectations in each of the trailing four quarters, with the average being 196.4%. In the last reported quarter, Repligen delivered an earnings surprise of 114.3%.
Shares of the company have surged 48.7% so far this year against the industry’s 14% decline.
Image Source: Zacks Investment Research
Let’s see how things have shaped up for the quarter to be reported.
Factors to Consider
Organogenesis earns revenues from the sale of several products, which can be categorized into Advanced Wound Care (AWC), and Surgical & Sports Medicine (SSM). The AWC segment focuses on the treatment of chronic and acute wounds across various treatment settings while the SSM segment concentrates on products that support the healing of musculoskeletal injuries, including degenerative conditions such as osteoarthritis and tendonitis.
In the last reported quarter, total revenues were significantly up year over year driven by strong demand across both the segments, especially the AWC product business that registered growth of 87% year over year. We anticipate this trend to have continued in the third quarter.
The sales performance of the two business segments has most likely improved both sequentially and year over year in third-quarter 2021.
Organogenesis also categorizes total product revenues into two groups — PuraPly product revenues and non-PuraPly product revenues. In the last reported quarter, the company reported that the non-PuraPly product sales were significantly up year over year. The same trend is most likely to have continued in the third quarter.
The SSM segment reported favorable growth during second-quarter 2021 despite two of its products — ReNu (for knee osteoarthritis) and NuCel (for bony fusion in the lumbar spine) — coming off the market after May 31, 2021, following an FDA guidance that required these products to obtain a biologics license application (BLA) approval for commercialization. Earlier, these products were allowed to be commercially distributed without prior FDA approval.
While the company is conducting clinical studies on ReNu to support the potential approval for a BLA for the treatment of knee osteoarthritis, it has decided to discontinue the clinical development of NuCel. The company is currently enrolling patients in a phase III study evaluating the safety and efficacy of ReNu in patients with knee osteoarthritis.
Earnings Whispers
Our proven model does not conclusively predict an earnings beat for Organogenesis this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. Unfortunately, that is not the case here as you will see below. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Earnings ESP: Organogenesis’ Earnings ESP is 0.00% as both the Most Accurate Estimate and the Zacks Consensus Estimate are pegged at 6 cents per share.
Zacks Rank: Organogenesiscurrently carries a Zacks Rank #3.
Here are a few stocks you may want to consider as our model shows that these have the right combination of elements to beat on earnings this reporting cycle:
FibroGen (FGEN - Free Report) has an Earnings ESP of +108.22% and a Zacks Rank #3 at present. The company is scheduled to report quarterly earnings on Nov 9.
Regeneron (REGN - Free Report) has an Earnings ESP of +8.78% and a Zacks Rank #1, presently. The company is scheduled to report quarterly earnings on Nov 4.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Organogenesis (ORGO) to Post Q3 Earnings: What's in Store?
We expect investors to focus on the sales performance of Organogenesis Holdings’ (ORGO - Free Report) two segments — Advanced Wound Care, and Surgical & Sports Medicine — when it reports third-quarter 2021 results on Nov 9, after market close.
The company’s earnings surprise history is pretty impressive. It surpassed expectations in each of the trailing four quarters, with the average being 196.4%. In the last reported quarter, Repligen delivered an earnings surprise of 114.3%.
Shares of the company have surged 48.7% so far this year against the industry’s 14% decline.
Let’s see how things have shaped up for the quarter to be reported.
Factors to Consider
Organogenesis earns revenues from the sale of several products, which can be categorized into Advanced Wound Care (AWC), and Surgical & Sports Medicine (SSM). The AWC segment focuses on the treatment of chronic and acute wounds across various treatment settings while the SSM segment concentrates on products that support the healing of musculoskeletal injuries, including degenerative conditions such as osteoarthritis and tendonitis.
In the last reported quarter, total revenues were significantly up year over year driven by strong demand across both the segments, especially the AWC product business that registered growth of 87% year over year. We anticipate this trend to have continued in the third quarter.
The sales performance of the two business segments has most likely improved both sequentially and year over year in third-quarter 2021.
Organogenesis also categorizes total product revenues into two groups — PuraPly product revenues and non-PuraPly product revenues. In the last reported quarter, the company reported that the non-PuraPly product sales were significantly up year over year. The same trend is most likely to have continued in the third quarter.
The SSM segment reported favorable growth during second-quarter 2021 despite two of its products — ReNu (for knee osteoarthritis) and NuCel (for bony fusion in the lumbar spine) — coming off the market after May 31, 2021, following an FDA guidance that required these products to obtain a biologics license application (BLA) approval for commercialization. Earlier, these products were allowed to be commercially distributed without prior FDA approval.
While the company is conducting clinical studies on ReNu to support the potential approval for a BLA for the treatment of knee osteoarthritis, it has decided to discontinue the clinical development of NuCel. The company is currently enrolling patients in a phase III study evaluating the safety and efficacy of ReNu in patients with knee osteoarthritis.
Earnings Whispers
Our proven model does not conclusively predict an earnings beat for Organogenesis this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. Unfortunately, that is not the case here as you will see below. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Earnings ESP: Organogenesis’ Earnings ESP is 0.00% as both the Most Accurate Estimate and the Zacks Consensus Estimate are pegged at 6 cents per share.
Zacks Rank: Organogenesiscurrently carries a Zacks Rank #3.
Organogenesis Price and EPS Surprise
Organogenesis price-eps-surprise | Organogenesis Quote
Stocks to Consider
Here are a few stocks you may want to consider as our model shows that these have the right combination of elements to beat on earnings this reporting cycle:
Cytokinetics (CYTK - Free Report) currently has an Earnings ESP of +2.82% and a Zacks Rank #2. The company is scheduled to report quarterly earnings on Nov 3. You can see the complete list of today’s Zacks #1 Rank stocks here.
FibroGen (FGEN - Free Report) has an Earnings ESP of +108.22% and a Zacks Rank #3 at present. The company is scheduled to report quarterly earnings on Nov 9.
Regeneron (REGN - Free Report) has an Earnings ESP of +8.78% and a Zacks Rank #1, presently. The company is scheduled to report quarterly earnings on Nov 4.